Immunology IBD Quiz
Preview:
What is the Ustekinumab maintenance dose for a patient with CD weighing 100 kg?
A. 90 mg s.c.
B. 260 mg i.v.
C. 290 mg s.c.
D. 520 mg s.c.
What was the CDAI range of patients with Crohn’s disease in UNITI-1 and UNITI-2?
A. 300–450
B. 220–450
C. 150–350
D. 280–400
UST is inhibiting IL12 & IL23 due to its action on ………… subunit
A. p19
B. p40
C. p75
How long is the duration of innate immunity action after infection?
A. 0 to 12 hours
B. 0 to 24 hours
C. 12 to 72 hours
D. 24 to 72 hours
What was the primary endpoint for both the UNITI-1 and UNITI-2 studies?
A. CDAI-70 response at Week 8
B. CDAI-90 response at Week 6 and clinical response at Week 6
C. Clinical response at Week 6
D. Clinical remission at Week 8
All of the below were in the inclusion criteria for UNIFI patients EXCEPT:
A. ≥18 years of age
B. Moderate-to-severe UC diagnosis ≥3 months before screening
C. Stable doses of 5-ASA and immunomodulators were maintained from induction BL through maintenance Week 44
D. Prior TNF-antagonist therapy was discontinued ≥8 weeks and vedolizumab ≥4 months before study entry; other conventional therapies were discontinued ≥2-4 weeks before study entry
E. Oral corticosteroids were maintained at a stable dose during induction and tapered upon entering maintenance
NK cells and T cells are major components of the adaptive immunity
A. TRUE
B. FALSE
Which of the following was NOT a key finding from the UNIFI induction study of Ustekinumab in UC?
A. Symptomatic improvement observed as early as Week 2
B. Clinical response in ~80% of patients at Week 16
C. CS-free remission in ~80% of patients at Week 24
What were the treatment arms, and their duration, for the UNITI-1 and UNITI-2 induction studies?
A. Ustekinumab ~6 mg/kg or 130 mg, versus adalimumab over a 12-week period
B. Ustekinumab ~3 mg/kg or 220 mg versus vedolizumab over an 8-week period
C. Ustekinumab ~6 mg/kg or 130 mg, versus placebo over an 8-week period
D. Ustekinumab ~4 mg/kg versus adalimumab and placebo over a 12-week period
Which of the below subunits is specific to IL23
A. p19
B. p40
C. p75
Stelara is approved for ASUC (Acute Severe UC) treatment
A. TRUE
B. FALSE
Which biologic consists of Human p75 TNF receptor
A. Secukinumab
B. Abatacept
C. Etanercept
D. Adalimumab
Vedolizumab is a fully human Ab that works on B cell activation
A. TRUE
B. FALSE
Adalimumab is a humanized mab produced by phage display Technology
A. TRUE
B. FALSE
What was the main objective of the IM-UNITI maintenance study?
A. To investigate the efficacy and safety of Ustekinumab 90 mg q8w or q12w versus placebo over a 44-week period
B. To investigate the efficacy and safety of Ustekinumab 130 mg q5w or q10w versus placebo over a 44-week period
C. To investigate the efficacy and safety of Ustekinumab 80 mg q12w versus adalimumab or placebo over a 44-week period
D. To investigate the efficacy and safety of Ustekinumab ~6 mg/kg or 130 mg versus placebo over a 48-week period